Torrent Pharma Ltd. (BSE: 500420) is an Ahmedabad, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹1,79,494 Cr, it ranks #52 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹4,670.00 (as of 16 Nov 2026), the share price is 11.0% below its 52-week high of ₹5,250.00 and 27.2% above its 52-week low of ₹3,672.30. The share price is up 30.4% over one year and down 5.0% over three months.
| Current Price | ₹4,670.00 |
|---|---|
| Market Cap | ₹1,79,494 Cr |
| BSE Code | 500420 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 73.6 |
| Return on Equity | 16.98% |
| Return on Assets | 7.25% |
| 52-Week Range | ₹3,672.30 – ₹5,250.00 |
| 1-Year Price Change | +30.4% |
| 3-Month Price Change | -5.0% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.38% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.torrentpharma.com |
| Revenue | ₹4,979 Cr |
|---|---|
| Net Profit | ₹534 Cr |
| Net Margin | 10.7% |
| EPS (Basic) | ₹14.05 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Torrent Pharma Ltd. reported revenue of ₹4,979 Cr in Q2 FY27, up 50.8% from ₹3,302 Cr in Q2 FY26 and up 1.2% from ₹4,921 Cr in Q1 FY27. It posted a net profit of ₹534 Cr for the quarter, against a net profit of ₹591 Cr in Q2 FY26 (down 9.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,959 Cr (Q4 FY25) to ₹4,979 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹4,979 Cr | ₹534 Cr | 10.7% |
| Q1 FY27 | ₹4,921 Cr | ₹566 Cr | 11.5% |
| Q4 FY26 | ₹4,197 Cr | ₹364 Cr | 8.7% |
| Q3 FY26 | ₹3,303 Cr | ₹635 Cr | 19.2% |
| Q2 FY26 | ₹3,302 Cr | ₹591 Cr | 17.9% |
| Q1 FY26 | ₹3,178 Cr | ₹548 Cr | 17.2% |
| Q4 FY25 | ₹2,959 Cr | ₹498 Cr | 16.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 60.78% of Torrent Pharma Ltd.'s shares as of Sept 2026, against 68.31% in Dec 2025 (−7.53 percentage points). Delivery averaged 60.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, cosmo-dermatology, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Limited.
1. Generic Formulation Business-This segment engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. It also engages in contract manufacturing business.
1. Generic Formulation Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Torrent Pharma Ltd. is trading at ₹4,670.00, with a market capitalisation of ₹1,79,494 Cr.
Torrent Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Torrent Pharma Ltd. has a P/E of 73.6 and a return on equity of 16.98%.
Torrent Pharma Ltd. is listed on the BSE under the scrip code 500420.
Torrent Pharma Ltd.'s share price is up 30.4% over one year and down 5.0% over three months. Its 52-week range is ₹3,672.30 to ₹5,250.00.
In Q2 FY27, Torrent Pharma Ltd. reported revenue of ₹4,979 Cr and net profit of ₹534 Cr, with basic EPS of ₹14.05 (consolidated, parsed from the company's exchange filing).
Torrent Pharma Ltd. reported revenue of ₹4,979 Cr in Q2 FY27, up 50.8% from ₹3,302 Cr in Q2 FY26 and up 1.2% from ₹4,921 Cr in Q1 FY27.
Promoters held 60.78% of Torrent Pharma Ltd.'s shares as of Sept 2026, against 68.31% in Dec 2025 (−7.53 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.